QuantuMDx: Jonathan O'Halloran, Neil Butler, Elaine Warburton, John Burn

Multi-omic spatial sequencing company ReadCoor has appointed Dennis Flannelly to its board of directors. Flannelly is currently head of precision medicine for US oncology at Merck, known as MSD outside of the US and Canada. Prior to joining Merck, Flannelly served in leadership roles at PerkinElmer, most recently as VP and general manager of the immunodiagnostics business, and previously as VP of maternal-fetal health. Flannelly has also served as global director of clinical marketing for Thermo Fisher Scientific's immunodiagnostics business. He also served as the head of US marketing for Thermo Fisher.

Cergentis of Utrecht, the Netherlands, this week announced a number of new appointments. Joris Schuurmans has become the firm's CEO, replacing Jan Dekker. Schuurmans joins Cergentis from Skyline Dx, where he led the melanoma program. Previously, he held senior executive positions at Biocartis and at MyCartis.

Further, Dirk Pollet and Maja Sanders have joined the company's supervisory board. Pollet is CEO of Enzyre and is the former CEO of Multiplicom, which was acquired by Agilent Technologies. Sanders holds supervisory roles at various organizations and has managerial experience in the private equity industry.

NeoGenomics announced the appointment of Cynthia Dieter as chief accounting officer and controller, effective June 22. Before coming to NeoGenomics, Dieter was the senior director of corporate accounting at Viasat. She has also served in multiple roles at DJO Global, including VP and assistant corporate controller, VP and vista controller, and director of financial reporting and planning. 

In addition, Dieter has been the manager of financial reporting at Captiva Software and audit manager for Ernst and Young. 

T2 Biosystems has appointed Thierry Bernard, Ninfa Saunders, and Robin Toft to its board of directors. Bernard currently serves as CEO of Qiagen, Saunders is president and CEO of Navicent Health, and Toft is founder and CEO of Toft Group and previously served as senior vice president of commercial operations at Roche Molecular Diagnostics. T2 Biosystems also announced that Michael Cima, Adrian Jones, and Stanley Lapidus will be leaving the firm's board of directors.

IonPath has appointed Brad Nelson as senior vice president of marketing and corporate strategy. Nelson will lead marketing, product management, and application functions related to the company's multiplexed ion beam Imaging technology. Nelson most recently served as VP of marketing at Magnolia Medical Technologies. Prior to that he was head of marketing and director of corporate development at Labcyte (now part of Danaher). He also previously led marketing efforts at Velocity11, which was acquired by Agilent.

Laboratory for Advanced Medicine has appointed Samuel Tong as CEO for its operations in China. He joins the company from medical research organization NAMSA where he was vice president and general manager of the Asia-Pacific region. Prior to that, he was VP and GM for greater China at Qiagen. Tong was also business unit director of diagnostics systems for greater China at Becton Dickinson, and country manager of China at Abbott Vascular.

Scipher Medicine has named Jerry Conway as senior vice president of market access. He will focus on patient access to Scipher's precision diagnostic tools beginning with PrismRA, a molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid arthritis, and is slated to launch later this year. Conway most recently served as executive vice president at CDx Diagnostics.